April 30, 2012
Health Awareness Topics - May 2012
- Arthritis Awareness Month (see related guidelines)
- Hepatitis Awareness Month (see related guidelines)
- Melanoma/Skin Cancer Detection and Prevention Month (see related guidelines and guideline synthesis)
- National Asthma and Allergy Awareness Month (see related guidelines)
- National Celiac Disease Awareness Month (see related guidelines and guideline synthesis)
- National High Blood Pressure Education Month (see related guidelines)
- National Osteoporosis Awareness Month (see related guidelines and guideline synthesis)
Visit the updated Hospital-Acquired Conditions page for evidence-based resources available on the NGC Web site to assist users in the prevention of the CMS-identified hospital-acquired conditions.
The Guidelines International Network (G-I-N) Conference 2012, will be held August 22-25, 2012 in Berlin, Germany. Registration is now open.
U.S. Food and Drug Administration (FDA) Advisory
- April 26, 2012: Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs : FDA notified healthcare professionals that the Victrelis drug label has been revised to state that co-administration of Victrelis (boceprevir), a hepatitis C virus (HCV) protease inhibitor, along with certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors, is not recommended.
- April 20, 2012: Aliskiren-containing Medications : FDA notified healthcare professionals of possible risks when using blood pressure medicines containing aliskiren with other drugs called angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with diabetes or kidney (renal) impairment. These drug combinations should not be used (are contraindicated) in patients with diabetes. In addition, avoid use of aliskiren with ARBs or ACEIs in patients with moderate to severe renal impairment. The labels for the aliskiren drugs are being updated based on preliminary data from a clinical trial